Related Industry Reports:
- Clinical Trial Recruitment Strategies in Oncology - Online Recruitment Methods and Use of IT - enabled Patient Management Systems will Reduce Recruitment Time and Cost
- The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
- Non-Small-Cell Lung Cancer (NSCLC) - Drug Pipeline Analysis and Market Forecasts to 2015
- Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
A Comparative Study of Intravenous Ibandronate and Pamindronate in Patients With Bone Metastases From Breast or Lung Cancer: Effect on Metastatic Bone Pain.
American journal of therapeutics 2010 Jul 10; In press
Heras P, Hatzopoulos A, Heras V, Kritikos N, Karagiannis S, Kritikos K
1General Hospital of Nafplio, Department of Internal Medicine, Nafplio, Greece; 2General Hospital of Cos, Department of Internal Medicine, Cos, Greece; and 3Hellenic Medical Society for the Study of Psychosomatic Problems, Athens, Greece.
We compared the effects of ibandronate and pamindronate in patients with bone metastases from breast or lung cancer and we found that ibandronate is superior to pamindronate in alleviating pain, improving mobility and quality of life, and reducing bone resorption indices in patients with bone metastases from breast or lung cancer.
Keywords: Ibandronate Pamindronate Lung Cancer Bone Pain